Durvalumab-induced organizing pneumonia in extensive-stage small cell lung cancer: A case report and literature review
The etoposide-carboplatin and anti-PD-L1 combination has become the standard-of-care for patients with extensive-stage small cell lung cancer (ES-SCLC). This combinational strategy is well tolerated with manageable immune-related adverse effects (irAEs). In this report, we presented a rare immediate...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Radiology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1930043325000743 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850030182906200064 |
|---|---|
| author | Guoxin Wang, MD Wenjie Yan, MD Jun Cai, MD Fang Zhang, MD Tangfeng Lv, MD Mingxiang Ye, MD, PhD |
| author_facet | Guoxin Wang, MD Wenjie Yan, MD Jun Cai, MD Fang Zhang, MD Tangfeng Lv, MD Mingxiang Ye, MD, PhD |
| author_sort | Guoxin Wang, MD |
| collection | DOAJ |
| description | The etoposide-carboplatin and anti-PD-L1 combination has become the standard-of-care for patients with extensive-stage small cell lung cancer (ES-SCLC). This combinational strategy is well tolerated with manageable immune-related adverse effects (irAEs). In this report, we presented a rare immediate irAE after one course of anti-tumor treatment. The patient with ES-SCLC was treated with first-line etoposide-carboplatin chemotherapy and Durvalumab immunotherapy. After one cycle of indicated treatment, the patient developed persistent high-grade fever with extensive consolidation, surrounding by ground glass opacifications. The lesions did not respond to empirical antibiotics and the results for pathogen testing were negative. Histological analysis of biopsy sample yielded organizing pneumonia that was very likely to associate with Durvalumab treatment. The patient was therefore treated with prednisolone that resulted in a rapid radiological improvement. The reporting of this case is imperative for informing acute onset of irAE in patients with ES-SCLC treated with anti-PD-L1 immunotherapy. Differential diagnosis of infection, tumor progression and exacerbation of underlying illness should be considered before the initiation of prednisolone therapy. |
| format | Article |
| id | doaj-art-28998917cfda47ce8727d1194fa1c969 |
| institution | DOAJ |
| issn | 1930-0433 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Radiology Case Reports |
| spelling | doaj-art-28998917cfda47ce8727d1194fa1c9692025-08-20T02:59:18ZengElsevierRadiology Case Reports1930-04332025-05-012052253225710.1016/j.radcr.2025.01.072Durvalumab-induced organizing pneumonia in extensive-stage small cell lung cancer: A case report and literature reviewGuoxin Wang, MD0Wenjie Yan, MD1Jun Cai, MD2Fang Zhang, MD3Tangfeng Lv, MD4Mingxiang Ye, MD, PhD5Department of Respiratory Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaDepartment of Respiratory Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaDepartment of Radiology, Medical Imaging Center, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaDepartment of Respiratory Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaDepartment of Respiratory Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, ChinaDepartment of Respiratory Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China; Corresponding author.The etoposide-carboplatin and anti-PD-L1 combination has become the standard-of-care for patients with extensive-stage small cell lung cancer (ES-SCLC). This combinational strategy is well tolerated with manageable immune-related adverse effects (irAEs). In this report, we presented a rare immediate irAE after one course of anti-tumor treatment. The patient with ES-SCLC was treated with first-line etoposide-carboplatin chemotherapy and Durvalumab immunotherapy. After one cycle of indicated treatment, the patient developed persistent high-grade fever with extensive consolidation, surrounding by ground glass opacifications. The lesions did not respond to empirical antibiotics and the results for pathogen testing were negative. Histological analysis of biopsy sample yielded organizing pneumonia that was very likely to associate with Durvalumab treatment. The patient was therefore treated with prednisolone that resulted in a rapid radiological improvement. The reporting of this case is imperative for informing acute onset of irAE in patients with ES-SCLC treated with anti-PD-L1 immunotherapy. Differential diagnosis of infection, tumor progression and exacerbation of underlying illness should be considered before the initiation of prednisolone therapy.http://www.sciencedirect.com/science/article/pii/S1930043325000743Extensive-stage small cell lung cancerAnti-PD-L1 immunotherapyImmune-related adverse effectsOrganizing pneumoniaGround glass opacifications |
| spellingShingle | Guoxin Wang, MD Wenjie Yan, MD Jun Cai, MD Fang Zhang, MD Tangfeng Lv, MD Mingxiang Ye, MD, PhD Durvalumab-induced organizing pneumonia in extensive-stage small cell lung cancer: A case report and literature review Radiology Case Reports Extensive-stage small cell lung cancer Anti-PD-L1 immunotherapy Immune-related adverse effects Organizing pneumonia Ground glass opacifications |
| title | Durvalumab-induced organizing pneumonia in extensive-stage small cell lung cancer: A case report and literature review |
| title_full | Durvalumab-induced organizing pneumonia in extensive-stage small cell lung cancer: A case report and literature review |
| title_fullStr | Durvalumab-induced organizing pneumonia in extensive-stage small cell lung cancer: A case report and literature review |
| title_full_unstemmed | Durvalumab-induced organizing pneumonia in extensive-stage small cell lung cancer: A case report and literature review |
| title_short | Durvalumab-induced organizing pneumonia in extensive-stage small cell lung cancer: A case report and literature review |
| title_sort | durvalumab induced organizing pneumonia in extensive stage small cell lung cancer a case report and literature review |
| topic | Extensive-stage small cell lung cancer Anti-PD-L1 immunotherapy Immune-related adverse effects Organizing pneumonia Ground glass opacifications |
| url | http://www.sciencedirect.com/science/article/pii/S1930043325000743 |
| work_keys_str_mv | AT guoxinwangmd durvalumabinducedorganizingpneumoniainextensivestagesmallcelllungcanceracasereportandliteraturereview AT wenjieyanmd durvalumabinducedorganizingpneumoniainextensivestagesmallcelllungcanceracasereportandliteraturereview AT juncaimd durvalumabinducedorganizingpneumoniainextensivestagesmallcelllungcanceracasereportandliteraturereview AT fangzhangmd durvalumabinducedorganizingpneumoniainextensivestagesmallcelllungcanceracasereportandliteraturereview AT tangfenglvmd durvalumabinducedorganizingpneumoniainextensivestagesmallcelllungcanceracasereportandliteraturereview AT mingxiangyemdphd durvalumabinducedorganizingpneumoniainextensivestagesmallcelllungcanceracasereportandliteraturereview |